Literature DB >> 3492164

Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease.

N R Anthonisen, J Manfreda, C P Warren, E S Hershfield, G K Harding, N A Nelson.   

Abstract

The effects of broad-spectrum antibiotic and placebo therapy in patients with chronic obstructive pulmonary disease in exacerbation were compared in a randomized, double-blinded, crossover trial. Exacerbations were defined in terms of increased dyspnea, sputum production, and sputum purulence. Exacerbations were followed at 3-day intervals by home visits, and those that resolved in 21 days were designated treatment successes. Treatment failures included exacerbations in which symptoms did not resolve but no intervention was necessary, and those in which the patient's condition deteriorated so that intervention was necessary. Over 3.5 years in 173 patients, 362 exacerbations were treated, 180 with placebo and 182 with antibiotic. The success rate with placebo was 55% and with antibiotic 68%. The rate of failure with deterioration was 19% with placebo and 10% with antibiotic. There was a significant benefit associated with antibiotic. Peak flow recovered more rapidly with antibiotic treatment than with placebo. Side effects were uncommon and did not differ between antibiotic and placebo.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3492164     DOI: 10.7326/0003-4819-106-2-196

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  503 in total

Review 1.  Home treatment of COPD exacerbations.

Authors:  D S Postma; N H Ten Hacken; H A Kerstjens; G H Koëter
Journal:  Thorax       Date:  1999-08       Impact factor: 9.139

Review 2.  Factors influencing airway inflammation in chronic obstructive pulmonary disease.

Authors:  A Hill; S Gompertz; R Stockley
Journal:  Thorax       Date:  2000-11       Impact factor: 9.139

3.  Measuring symptomatic and functional recovery in patients with community-acquired pneumonia.

Authors:  J P Metlay; M J Fine; R Schulz; T J Marrie; C M Coley; W N Kapoor; D E Singer
Journal:  J Gen Intern Med       Date:  1997-07       Impact factor: 5.128

4.  Oxidant-antioxidant balance in patients with COPD.

Authors:  Ismail Hanta; Ali Kocabas; Necmiye Canacankatan; Sedat Kuleci; Gulsah Seydaoglu
Journal:  Lung       Date:  2006 Mar-Apr       Impact factor: 2.584

Review 5.  Management of an acute exacerbation of copd: are we ignoring the evidence?

Authors:  M K Johnson; R D Stevenson
Journal:  Thorax       Date:  2002-10       Impact factor: 9.139

6.  [Austrian Society for Pulmonary Diseases and Tuberculosis. Consensus concerning the management of chronic obstructive pulmonary diseases (COPD). Revised draft 2004].

Authors:  Lutz H Block; Otto C Burghuber; Sylvia Hartl; Hartmut Zwick
Journal:  Wien Klin Wochenschr       Date:  2004-04-30       Impact factor: 1.704

7.  Trimethoprim- sulfamethoxazole: pharmacokinetics, clinical uses, and adverse reactions.

Authors:  M A Kielhofner
Journal:  Tex Heart Inst J       Date:  1990

8.  [Antimicrobial treatment of patients with severe acute exacerbation of COPD].

Authors:  B Klapdor; S Ewig
Journal:  Med Klin Intensivmed Notfmed       Date:  2012-03-22       Impact factor: 0.840

9.  Noninvasive ventilation in hypercapnic acute respiratory failure due to chronic obstructive pulmonary disease vs. other conditions: effectiveness and predictors of failure.

Authors:  Jason Phua; Kien Kong; Kang Hoe Lee; Liang Shen; T K Lim
Journal:  Intensive Care Med       Date:  2005-03-02       Impact factor: 17.440

10.  Randomised double-blind comparison of oral gatifloxacin and co-amoxiclav for acute exacerbation of chronic Bronchitis.

Authors:  M Solèr; H Lode; R Baldwin; J H A Levine; A J M Schreurs; J A van Noord; F P V Maesen; M Zehrer
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-03-05       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.